Anne C. Chiang

Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Lauren A. Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang et autres

In the version of this article initially published, ref. 10 was cited twice and has been replaced by an omitted reference (Faivre E. J. et al. Cancer Re s. https://doi.org/10.1158/1538-7445.AM2024-3148 (2024)), now cited as ref. 11 in the last paragraph of the …

us, kr, es, il, jp (code pays fourni par la source)

ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).

Lauren Averett Byers, B K Cho, Alissa J. Cooper, Anne C. Chiang et autres

8008 Background: SCLC is an aggressive cancer with poor prognosis and limited treatment options. Seizure-related 6 homolog (SEZ6) is overexpressed in SCLC. ABBV-706 is a SEZ6-targeting antibody-drug conjugate with topoisomerase 1-inhibitor payload. Here we report updated data from a phase 1 study …

us, kr, il, jp, es (code pays fourni par la source)

Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial

Pedro Rocha, Manish R. Patel, Yi-Long Wu, Jun Zhao et autres

Abstract Background: Brain metastasis (BM) is prevalent in extensive-stage small-cell lung cancer (ES-SCLC) and also a common cause for treatment failure. BM remains as an unmet need with limited treatment options available such as palliative radiotherapy. ZL-1310 is a novel antibody-drug conjugate …

es, us, cn, Éthiopie (code pays fourni par la source)

Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non–Small Cell Lung Cancer

Wang Xiao, D. Lee, Szu‐Chun Yang, Yimeng Li et autres

BACKGROUND: Patients with advanced non-small cell lung cancer (aNSCLC) are recommended to undergo molecular testing for targetable genomic alterations. However, as high-throughput methods are increasingly used, long test turnaround time (TAT) may lead to lower receipt of appropriate targeted therapy. Guidelines recommend …

us, tw (code pays fourni par la source)

OA06.04 Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R/R SCLC

Lauren A. Byers, Byoung Chul Cho, Alan Cooper, Anne C. Chiang et autres

us, kr, jp, es (code pays fourni par la source)

2777P Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer

Jair Bar, Afshin Dowlati, L.A. Byers, B.C. Cho et autres

il, us, kr, de (code pays fourni par la source)

2778P ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with relapsed/refractory (R/R) small cell lung cancer (SCLC): Circulating biomarker and molecular response analyses

Alissa J. Cooper, Lujia Wang, Aiping Luo, Anne C. Chiang et autres

us, es (code pays fourni par la source)

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Amin H. Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat et autres

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. …

us, no, es, be, de, it, gb (code pays fourni par la source)

Small-Cell Lung Cancer Updates

Yunan Nie, Anne C. Chiang

Small-cell lung cancer (SCLC) is a high-grade, aggressive neuroendocrine tumor with a particularly poor prognosis, characterized by early metastases and rapid development of therapy resistance. There have historically been few treatment options for advanced or extensive stage SCLC, which comprises 70% of …

us (code pays fourni par la source)

Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer

Juanyi Tan, Szu‐Chun Yang, Michaela A. Dinan, Anne C. Chiang et autres

Importance: Targeted therapies and immunotherapies prolong survival but are associated with high costs for patients with advanced non-small cell lung cancer (aNSCLC). To date, little is known about survival and medication cost by biomarker status in the US. Objective: To estimate survival …

us, tw (code pays fourni par la source)

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study

Philip C. Mack, Mary W. Redman, Hanna Tukachinsky, David Kozono et autres

PURPOSE: ctDNA is a powerful diagnostic companion to tissue profiling. Tumor fraction (TF) is a global assessment of an individual's ctDNA burden. We evaluated the impact of plasma TF on mutation detection and clinical outcomes in patients with previously treated, advanced non-small …

us (code pays fourni par la source)

Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

Yunan Nie, Anna Wurtz, Fangyong Li, Kurt A. Schalper et autres

8544 Background: Immunotherapy with PD1 axis inhibitors is approved for metastatic non-small cell lung cancer (NSCLC). Outside of tumor PD-L1 expression, which predicts immunotherapy sensitivity in metastatic NSCLC, no clinicopathologic characteristics have been identified that reliably predict long-term survival after immunotherapy. To …

us (code pays fourni par la source)